Literature DB >> 32020469

Editorial: advances in neuro-oncology and clinical treatment-from ASNO 2019.

Pin-Yuan Chen1,2,3, Kuo-Chen Wei4,5.   

Abstract

The 16th Annual Meeting of the Asian Society for Neuro-Oncology was successfully held in Taipei, September 26-29. The diverse, in-depth experiences sharing in the conference contributed the fruitful result. Here we selected several important manuscripts to represent the advance of neuro-oncology and clinical treatment in Asia.

Keywords:  ASNO2019; Neuro-oncology; Treatment

Mesh：

Year:  2020        PMID： 32020469     DOI： 10.1007/s11060-019-03345-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  7 in total

1.  Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Use of Stereotactic Radiosurgery in the Treatment of Adults With Metastatic Brain Tumors.

Authors:  Jerome J Graber; Charles S Cobbs; Jeffrey J Olson
Journal:  Neurosurgery       Date:  2019-03-01       Impact factor: 4.654

2.  Radiomics as prognostic factor in brain metastases treated with Gamma Knife radiosurgery.

Authors:  Chih-Ying Huang; Cheng-Chia Lee; Huai-Che Yang; Chung-Jung Lin; Hsiu-Mei Wu; Wen-Yuh Chung; Cheng-Ying Shiau; Wan-Yuo Guo; David Hung-Chi Pan; Syu-Jyun Peng
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

3.  Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential.

Authors:  Patricia D B Tiburcio; David L Gillespie; Randy L Jensen; L Eric Huang
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

4.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew A Kanner; Santosh Kesari; David M Steinberg; Steven A Toms; Lynne P Taylor; Frank Lieberman; Antonio Silvani; Karen L Fink; Gene H Barnett; Jay-Jiguang Zhu; John W Henson; Herbert H Engelhard; Thomas C Chen; David D Tran; Jan Sroubek; Nam D Tran; Andreas F Hottinger; Joseph Landolfi; Rajiv Desai; Manuela Caroli; Yvonne Kew; Jerome Honnorat; Ahmed Idbaih; Eilon D Kirson; Uri Weinberg; Yoram Palti; Monika E Hegi; Zvi Ram
Journal:  JAMA       Date:  2015-12-15       Impact factor: 56.272

5.  Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.

Authors:  Chae-Yong Kim; Sun Ha Paek; Do-Hyun Nam; Jong-Hee Chang; Yong-Kil Hong; Jeong Hoon Kim; Oh Lyong Kim; Se-Hyuk Kim
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

6.  Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors.

Authors:  Sanford P C Hsu; Yi-Ching Chen; Hsin-Chien Chiang; Yi-Chun Huang; Cheng-Chung Huang; Hsin-Ell Wang; Yu-Shang Wang; Kwan-Hwa Chi
Journal:  J Neurooncol       Date:  2020-02-04       Impact factor: 4.130

Review 7.  Friend or foe-IDH1 mutations in glioma 10 years on.

Authors:  L Eric Huang
Journal:  Carcinogenesis       Date:  2019-11-25       Impact factor: 4.944
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.